Clinical trials: CMV
CMV, Prenatal Diagnosis
Does Normal Brain Imaging Predict Normal Neurodevelopmental Outcome in Fetuses With Proven Cytomegalovirus Infection?
Cytomegalovirus (CMV) is the largest member of the virus family Herpesviridae that infects almost all humans at some point in their lives (Ross, 2004).
- Conditions
- CMV, Prenatal Diagnosis, Ultrasound, MRI
- Trial name
- NCT00872703
- Where
- Israel
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Wolfson Medical Center
Pregnant Women, Cytomegalovirus Infections
The Maternal Cellular Immune System and Cytomegalovirus Intrauterine Infection
The purpose of this study is to find a correlation between function of cytomegalovirus -specific T cells and the probability for intrauterine transmission.
- Trial name
- NCT01081379
- Where
- Israel
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Shaare Zedek Medical Center
Opportunistic Fungal Infection, Opportunistic Viral Infection
T Lymphocytes for the Treatment of AdV, CMV, EBV, BKV and Aspergillus Fumigatus Infections After Allogeneic Stem Cell Transplantation
The purpose of the study is to determine the feasibility, safety and efficacy of administering rapidly-generated donor-derived pentavalent-specific T cells (Penta-STs) to mediate antiviral and antifungal activity in hematopoietic…
- Conditions
- Opportunistic Fungal Infection, Opportunistic Viral Infection, Bone Marrow Transplant Infection
- Trial name
- Penta-STs-001 (NCT05471661)
- Testing
- Pentavalent-specific T cells (penta-STs)
- Where
- 2 sites in Greece
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- George Papanicolaou Hospital
Arterial Occlusive Diseases, Atherosclerosis
Potential Role of CMV in Restenosis Following Angioplasty, in Atherosclerosis, and in Endothelial Dysfunction
The purpose of this study is to investigate whether the susceptibility of subjects to atherosclerosis is influenced by prior CMV exposure, whether the susceptability to endothelial dysfunction in patients with and in patients…
- Conditions
- Arterial Occlusive Diseases, Atherosclerosis, Coronary Disease, Cytomegalovirus Infections
- Trial name
- NCT00001531
- Where
- United States
- Volunteers
- 355 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Cytomegalovirus (CMV) Infections
V160 2-Dose and 3-Dose Regimens in Healthy Cytomegalovirus (CMV) Seronegative Females (V160-002)
This study evaluated the safety, tolerability, and efficacy of the cytomegalovirus (CMV) vaccine (V160) administered in a 2-dose or 3-dose regimen to healthy seronegative women 16 to 35 years of age.
- Trial name
- NCT03486834
- Testing
- V160
- Where
- 95 sites in United States, Australia and 5 more
- Volunteers
- 2,200 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infections, Immune Activation
The University of Zimbabwe College of Health Science (UZ-CHS) BIRTH COHORT Study
Background Commencement of lifelong highly active antiretroviral therapy (HAART) immediately after HIV diagnosis (option B+), for treatment of human immunodeficiency virus (HIV), has greatly improved maternal-infant health in sub…
- Conditions
- HIV Infections, Immune Activation, Comorbidities
- Trial name
- UZ-CHS-BC (NCT04087239)
- Testing
- HIV
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- University of Zimbabwe
Pregnancy Complications, Cytomegalovirus Infection
Cytomegalovirus (CMV) Infection in Pregnancy
The purpose of this study is to determine if (recurrent) cytomegalovirus (CMV) infection of the mother results in pregnancy complications such as preterm delivery, severe preeclampsia, poor fetal growth, or stillbirth.
- Trial name
- NCT00194155
- Where
- United States
- Volunteers
- 283 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Infections, Cytomegalovirus
Evaluation of the Long-term Persistence of GlaxoSmithKline (GSK) Biologicals' Candidate Cytomegalovirus (CMV) Vaccine
The purpose of this study is to evaluate the persistence of the vaccine induced immune responses at Month 48 (Year 4) and Month 60 (Year 5) in healthy subjects who received 3 doses of GSK Biologicals' candidate CMV vaccine…
- Trial name
- NCT01357915
- Testing
- Blood sampling, GSK149203A
- Where
- 2 sites in Belgium
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Cytomegalovirus Infection
Phase 1 Trial of CMV Towne Vaccine in Subjects Previously Received VCL CT02 Vaccine ID or IM
Objectives of this trial are to: 1. Evaluate the kinetics and magnitude of the CMV-specific immune response post-Towne challenge (3000 pfu) in healthy CMV-seronegative volunteers who received VCL CT02 administered ID or IM 9 to…
- Trial name
- NCT00370006
- Testing
- Towne CMV vaccine
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Nonneoplastic Condition
Vaccine Therapy in Preventing Cytomegalovirus in Healthy Participants
RATIONALE: Vaccines made from peptides may help the body build an immune response to kill cytomegalovirus. PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in preventing cytomegalovirus in…
- Trial name
- NCT00722839
- Testing
- PADRE-CMV fusion peptide vaccine, tetanus-CMV fusion peptide vaccine, agatolimod sodium
- Where
- United States
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Prenatal Infection, Congenital Infection
Congenital CYtoMEgalovirus Infection in VIEtnam (CYMEVIE)
To estimate the prevalence of congenital CMV infection in Vietnamese neonates and relating morbidity within 2-year follow-up. Along with evaluating the predictive value of the presence and the level of CMV replication in the…
- Conditions
- Prenatal Infection, Congenital Infection, Neonatal Disease
- Trial name
- CYMEVIE (NCT04822142)
- Where
- Vietnam
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Hanoi Obstetrics and Gynecology Hospital
Cytomegalovirus
A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age
The main purpose of study is to evaluate the safety and immunogenicity of different dose levels of mRNA-1647 versus control in healthy cytomegalovirus (CMV)-seronegative and CMV-seropositive female and male participants 9 to 15…
- Trial name
- NCT05575492
- Testing
- mRNA-1647
- Where
- 57 sites in United States, Canada and 1 more
- Volunteers
- 873 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Cytomegalovirus Infections
gB/MF59 Vaccine in Preventing Cytomegalovirus Infection in Healthy Adolescent Females
The purpose of this research study is to test the safety of and the body's response to an experimental cytomegalovirus (CMV) vaccine (called gB/MF59 vaccine).
- Trial name
- NCT00133497
- Testing
- MF-59, CMV gB vaccine
- Where
- 5 sites in United States
- Volunteers
- 409 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Cytomegalovirus (CMV)
Study of SHP620 (Maribavir) in Healthy Adults
The purpose of this study is to determine how an investigational treatment (maribavir) is handled by the body when administered with two already approved drugs (digoxin and dextromethorphan).
- Trial name
- NCT02775240
- Testing
- Digoxin, Maribavir, Dextromethorphan
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Shire
Alzheimer Disease, Late Onset
BCG and Plasma Amyloid in Non-Demented Adults
BCG vaccination, the most widely used vaccination in the world, is used to reduce risk of tuberculosis infection; it is used for other mycobacterial infections as well, benefiting leprosy and Buruli ulcer.
- Trial name
- NCT04449926
- Testing
- Bacillus of Calmette and Guerin (BCG)
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Mindful Diagnostics and Therapeutics, LLC
CMV Infection, Hematopoietic Stem Cell Transplantation
Immune Reconstitution to CMV After HSCT: Impact of Clinical Factors and Therapy Strategies
Cytomegalovirus (CMV) remains a significant cause of morbidity and mortality after hematopoietic stem cell transplantation (HSCT).
- Trial name
- NCT05656599
- Testing
- Letermovir
- Where
- 2 sites in China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Peking University People's Hospital
Cytomegalovirus Infections
A Study of Safety and Immune Response to Different Doses of a Cytomegalovirus Vaccine in Healthy Adults
The purpose of this study is to assess the safety, reactogenicity and immune response of the candidate CMV recombinant protein subunit (CMVsu) vaccine consisting of a combination of glycoproteins B (gB) and pentamer antigens…
- Trial name
- NCT05089630
- Testing
- Pentamer (low)/gB(low)/Adjuvant vaccine, Pentamer (med)/gB(low)/Adjuvant vaccine, Pentamer (med)/gB(med)/Adjuvant vaccine
- Where
- 18 sites in United States
- Volunteers
- 333 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Cytomegalovirus Infection
Safety and PK of MBX-400 (Cyclopropavir) in Normal Volunteers
This is a phase I safety, PK and food effect study of the CMV drug. In part 1 of the study, subjects will receive one of four dosage strengths of MBX-400 (100 mg once daily, 350 mg once daily; 750 mg once daily; and 1000 once…
- Trial name
- NCT02454699
- Testing
- MBX400
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Male Infertility
CMV IGG Antibodies in Semen as a Predictor for Blood Testis Barrier Damage
To assess whether the presence of Cytomegalovirus (CMV) Immunoglobulin G (IGG) antibodies in semen is a reliable predictor of male subfertility or infertility.
- Trial name
- NCT05302856
- Testing
- Blood test (CMV IGG, Anti sperm antibody, Testosterone levels)
- Where
- Israel
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Hadassah Medical Organization
Cytomegalovirus Infections
Safety Study of Human Anti-Cytomegalovirus Monoclonal Antibody
The purpose of this study is to compare the safety profile in healthy adult volunteers of single or multiple intravenous administrations of TCN-202 as compared with placebo.
- Trial name
- NCT01594437
- Testing
- TCN-202
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Theraclone Sciences, Inc.